ZA201503036B - Chimeric vaccine antigens against hepatitis c virus - Google Patents

Chimeric vaccine antigens against hepatitis c virus

Info

Publication number
ZA201503036B
ZA201503036B ZA2015/03036A ZA201503036A ZA201503036B ZA 201503036 B ZA201503036 B ZA 201503036B ZA 2015/03036 A ZA2015/03036 A ZA 2015/03036A ZA 201503036 A ZA201503036 A ZA 201503036A ZA 201503036 B ZA201503036 B ZA 201503036B
Authority
ZA
South Africa
Prior art keywords
virus
vaccine antigens
against hepatitis
antigens against
chimeric vaccine
Prior art date
Application number
ZA2015/03036A
Other languages
English (en)
Inventor
Blanco Sonia Gonzalez
Donato Gillian Martínez
Ponce De León Liz Alvarez-Lajonchere
Cañizares Yalena Amador
Noriega Daylen Aguilar
Carrera Santiago Dueñas
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of ZA201503036B publication Critical patent/ZA201503036B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2015/03036A 2012-11-05 2015-05-04 Chimeric vaccine antigens against hepatitis c virus ZA201503036B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c
PCT/CU2013/000006 WO2014067498A1 (es) 2012-11-05 2013-10-28 Antígenos vacunales quiméricos contra el virus de la hepatitis c

Publications (1)

Publication Number Publication Date
ZA201503036B true ZA201503036B (en) 2016-01-27

Family

ID=49724426

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/03036A ZA201503036B (en) 2012-11-05 2015-05-04 Chimeric vaccine antigens against hepatitis c virus

Country Status (15)

Country Link
US (1) US9676825B2 (enExample)
EP (1) EP2915544B1 (enExample)
JP (1) JP6259831B2 (enExample)
KR (1) KR102093495B1 (enExample)
CN (1) CN104837498B (enExample)
AR (1) AR093341A1 (enExample)
AU (1) AU2013339846B2 (enExample)
CA (1) CA2901346C (enExample)
CU (1) CU24112B1 (enExample)
ES (1) ES2644801T3 (enExample)
IN (1) IN2015DN03925A (enExample)
MX (1) MX358507B (enExample)
RU (1) RU2639504C2 (enExample)
WO (1) WO2014067498A1 (enExample)
ZA (1) ZA201503036B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986342C (en) 2015-07-07 2024-04-02 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
AU2017332854B2 (en) 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
US11596679B2 (en) * 2017-04-27 2023-03-07 Vanderbilt University Hepatitis C virus gene sequences and methods of use therefor
CN112601548A (zh) * 2018-03-16 2021-04-02 艾伯塔大学理事会 丙型肝炎病毒肽组合物及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039715D1 (de) 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
JP5405832B2 (ja) * 2006-01-04 2014-02-05 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｈｃｖ特異的なｔ細胞の活性化
US7256008B2 (en) 2006-01-06 2007-08-14 Abbott Laboratories Determination of concentration of FK778 by competitive immunoassay
US20110110974A1 (en) 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
JP5593220B2 (ja) * 2008-04-25 2014-09-17 東レ株式会社 Ｃ型肝炎ウイルス由来のキメラ遺伝子を含む核酸
EP2331125A4 (en) * 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment

Also Published As

Publication number Publication date
IN2015DN03925A (enExample) 2015-10-02
KR102093495B1 (ko) 2020-03-26
JP6259831B2 (ja) 2018-01-10
US20150307558A1 (en) 2015-10-29
CU24112B1 (es) 2015-08-27
KR20150079694A (ko) 2015-07-08
EP2915544B1 (en) 2017-08-09
JP2015536936A (ja) 2015-12-24
AU2013339846B2 (en) 2017-08-17
MX358507B (es) 2018-08-22
US9676825B2 (en) 2017-06-13
MX2015005651A (es) 2015-08-20
CN104837498B (zh) 2018-05-18
CN104837498A (zh) 2015-08-12
CU20120153A7 (es) 2014-06-27
ES2644801T3 (es) 2017-11-30
CA2901346A1 (en) 2014-05-08
WO2014067498A1 (es) 2014-05-08
RU2639504C2 (ru) 2017-12-21
AR093341A1 (es) 2015-06-03
RU2015121429A (ru) 2016-12-27
AU2013339846A1 (en) 2015-05-14
EP2915544A1 (en) 2015-09-09
CA2901346C (en) 2019-04-23

Similar Documents

Publication Publication Date Title
IL261204A (en) Influenza virus vaccines and their use
PL2935313T3 (pl) Szczepionki przeciwko wirusowi zapalenia wątroby typu b
ZA201404797B (en) Influenza virus vaccines and uses thereof
SG11201400743VA (en) Influenza virus vaccines and uses thereof
EP2806891A4 (en) VACCINES BASED ON PARAINFLUENZA VIRUS 5
IL235890A0 (en) vaccine
ZA201404516B (en) Vaccines against hpv
SG10201607787RA (en) Vaccine Composition Comprising An Inactivated Chikungunya Virus Strain
IL229307A0 (en) Inactivated dengue virus vaccine
ZA201306720B (en) Hepatitis c virus inhibitors
IL229270B (en) Hepatitis c virus inhibitors
EP2768517A4 (en) HEPATITIS C-VIRUS HEMMER
ZA201309356B (en) Hepatitis c virus inhibitors
ZA201503458B (en) Hepatitis c virus inhibitors
SG10201702292YA (en) Novel attenuated dengue virus strains for vaccine application
CU24112B1 (es) Antígenos vacunales quiméricos contra el virus de la hepatitis c
SI2850075T1 (sl) Piperazin-piperidinske spojine kot inhibitorji virusa hepatitisa C
GB201301119D0 (en) Viral vaccines
GB201210226D0 (en) Vaccine
GB201202090D0 (en) Vaccine
SG11201507455WA (en) Hepatitis b virus vaccines
SG11201505170WA (en) Dengue virus vaccine composition
AU2013905065A0 (en) Viral vaccine
AU2013905043A0 (en) Viral vaccine
AU2013904384A0 (en) Viral vaccine